Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline
Tubulis announced the successful completion of an upsized and oversubscribed €128 million ($138.8 million) Series B2 financing.
Search
Life Sciences
Tubulis announced the successful completion of an upsized and oversubscribed €128 million ($138.8 million) Series B2 financing.
Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announced the appointment of Eduardo...
Galecto, Inc., a clinical-stage biotechnology company and world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today...
Tubulis and Bristol Myers Squibb (NYSE: BMY) today announced that they have entered into a strategic license agreement to develop differentiated antibody-drug conjugates...
Domain Therapeutics (“Domain” or “the Company”), a drug discovery and development company focused on G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), today...
Galecto., a privately-held biotechnology company focused on the development of novel treatments for fibrosis and cancer, announced today the successful completion of a $64...
Tubulis announced the close of a €10.7 million Series A financing round to accelerate the development of a new class of highly stable and efficient antibody-drug conjugates...
MedinCell (FR0004065605 - MEDCL), a clinical stage pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas (the...
Domain Therapeutics announces today that it has secured a €3.5M ($3.9M) investment from existing shareholder Seventure Partners, to accelerate its next growth phase. Since...
Taking on board learnings from challenges already faced and focusing on advanced, longer-term studies of variables within microbiome research will be key to fostering...